MY8700597A - Acetal stabilized prostaglandin compositions - Google Patents

Acetal stabilized prostaglandin compositions

Info

Publication number
MY8700597A
MY8700597A MY597/87A MY8700597A MY8700597A MY 8700597 A MY8700597 A MY 8700597A MY 597/87 A MY597/87 A MY 597/87A MY 8700597 A MY8700597 A MY 8700597A MY 8700597 A MY8700597 A MY 8700597A
Authority
MY
Malaysia
Prior art keywords
acetal
prostaglandin compositions
stabilized prostaglandin
stabilized
compositions
Prior art date
Application number
MY597/87A
Other languages
English (en)
Inventor
Yu Cheng Der
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of MY8700597A publication Critical patent/MY8700597A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MY597/87A 1981-04-16 1987-12-30 Acetal stabilized prostaglandin compositions MY8700597A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/254,824 US4358603A (en) 1981-04-16 1981-04-16 Acetal stabilized prostaglandin compositions

Publications (1)

Publication Number Publication Date
MY8700597A true MY8700597A (en) 1987-12-31

Family

ID=22965721

Family Applications (1)

Application Number Title Priority Date Filing Date
MY597/87A MY8700597A (en) 1981-04-16 1987-12-30 Acetal stabilized prostaglandin compositions

Country Status (12)

Country Link
US (1) US4358603A (enExample)
EP (1) EP0063367B1 (enExample)
JP (1) JPS57181054A (enExample)
AT (1) ATE9061T1 (enExample)
AU (1) AU553104B2 (enExample)
CA (1) CA1168155A (enExample)
DE (1) DE3260600D1 (enExample)
HK (1) HK43987A (enExample)
IE (1) IE52854B1 (enExample)
MY (1) MY8700597A (enExample)
NZ (1) NZ200309A (enExample)
ZA (1) ZA822578B (enExample)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
AP9901643A0 (en) 1997-04-28 1999-10-02 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders.
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2463724A1 (en) * 2001-10-16 2003-04-24 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002367060A1 (en) * 2001-12-21 2003-07-30 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
CA2490692A1 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
MXPA05012281A (es) * 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
ATE439837T1 (de) * 2003-06-03 2009-09-15 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
EP1911754B1 (en) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050203184A1 (en) 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues
CA2583087C (en) 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CN1976693A (zh) 2004-05-20 2007-06-06 斯克里普斯研究所 转甲状腺素蛋白的稳定
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
JP2008505916A (ja) * 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド チロシンホスファターゼの酸素/窒素複素環阻害剤
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
EP1841749A1 (en) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
JP5242375B2 (ja) 2005-04-01 2013-07-24 ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア ホスホノ−ペント−2−エン−1−イルヌクレオシド及び類似体
KR101293935B1 (ko) * 2005-06-17 2013-08-08 리간드 파마슈티칼스 인코포레이티드 안드로겐 수용체 조절 화합물 및 방법
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
CN101466407B (zh) * 2006-01-24 2013-05-15 株式会社·R-技术上野 包含双环化合物的药物组合物和使所述双环化合物稳定的方法
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
NZ596091A (en) 2006-08-28 2012-07-27 Jolla Inst Allergy Immunolog Antagonistic human light-specific human monoclonal antibodies
EP2145878A3 (en) 2006-10-09 2010-02-24 Takeda Pharmaceutical Company Limited Aurora Kinase inhibitors
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2667961A1 (en) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
EP2564850B1 (en) 2007-09-25 2014-08-13 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
MX2010006972A (es) 2007-12-21 2010-08-26 Ligand Pharm Inc Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
KR101694931B1 (ko) 2009-01-06 2017-01-10 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
EP3064217B1 (en) 2009-01-06 2018-04-18 Galenagen, LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
EP2415767B1 (en) 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
JP5715625B2 (ja) 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2499282B1 (en) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US8710092B2 (en) * 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
EP2531501B1 (en) 2010-02-03 2013-11-20 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
MX347770B (es) 2011-04-21 2017-05-12 Curemark Llc Compuesto para el tratamiento de alteraciones neuropsiquiatricas.
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
EP2793583A4 (en) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc NOVEL NEUROMODULATORY CONNECTIONS
EP2822936B1 (en) 2012-03-07 2021-09-08 The McLean Hospital Corporation Aminoquinoline derivatives and uses thereof
CA3086105A1 (en) 2012-05-02 2013-11-07 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US8551535B1 (en) 2012-08-06 2013-10-08 Sarah McCann Homeopathic remedies and methods for enhancing weight loss
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
HK1219654A1 (zh) 2013-02-22 2017-04-13 University Of Southern California 用於治疗眼科疾病和病症的方法
WO2014165263A1 (en) 2013-03-12 2014-10-09 The Regents Of The University Of California, A California Corporation Gamma-secretase modulators
EP3935944A1 (en) 2013-03-15 2022-01-12 University Of Southern California, USC Stevens Compounds for the treatment of musculoskeletal diseases
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー,マモウン,エム. 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
MX381224B (es) 2014-10-31 2025-03-12 Massachusetts Gen Hospital Potentes moduladores de gamma-secretasa.
SI3333191T1 (sl) 2014-12-11 2021-03-31 Pierre Fabre Medicament Proti C10ORF54 protitelesa in uporaba le-teh
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
EP3289104B1 (en) 2015-04-29 2020-11-04 New York University Method for treating high-grade gliomas
EP3383390A4 (en) 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EA037302B9 (ru) 2016-02-12 2021-04-09 Фармаксис Лтд. Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
EP3426352A4 (en) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. CAMPTOTHECIN DERIVATIVES AND USES THEREOF
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
EP3675866B1 (en) 2017-09-01 2023-08-02 East Carolina University Ex vivo methods for activating immune cells
US20190216751A1 (en) 2017-11-15 2019-07-18 California State University Northridge Compositions and Methods for the Treatment and Prevention of Cancer
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
MX2021001347A (es) 2018-08-03 2021-04-13 Pharmaxis Ltd Inhibidores derivados de haloalilamina sulfona de lisil oxidasas y sus usos.
MA53238A (fr) 2018-08-17 2022-04-13 Eidos Therapeutics Inc Formules d'ag10
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
EP3956309A4 (en) 2019-04-19 2023-06-07 Ligand Pharmaceuticals Inc. CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND
CA3138406A1 (en) 2019-05-20 2020-11-26 Christopher J. MACNEVIN Narrow emission dyes, compositions comprising same, and methods for making and using same
JP7754724B2 (ja) 2019-05-20 2025-10-15 ニルバナ サイエンシーズ インク. 発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
BR112022004802A2 (pt) 2019-09-16 2022-08-23 Dice Alpha Inc Moduladores de il-17a e usos dos mesmos
WO2022006228A1 (en) 2020-06-30 2022-01-06 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2022192545A1 (en) 2021-03-10 2022-09-15 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
JP2024539134A (ja) 2021-10-22 2024-10-28 プロセッタ バイオサイエンシズ, インク. 新規な宿主標的汎呼吸器抗ウイルス小分子治療薬
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
CN118922189A (zh) 2022-03-02 2024-11-08 线粒体能量有限公司 衍生自烟酸和核糖的新型前药
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749800A (en) * 1971-11-01 1973-07-31 Upjohn Co Stable composition for dispensing pge2
US3833612A (en) * 1971-11-24 1974-09-03 Merck & Co Inc Derivatives of 5-oxo-1 beta-cyclopentane-heptanoic acid,5-ethylene acetals
US4178457A (en) * 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4178454A (en) * 1978-10-11 1979-12-11 Toray Industries, Inc. Stabilized prostaglandin E composition

Also Published As

Publication number Publication date
NZ200309A (en) 1985-03-20
JPS57181054A (en) 1982-11-08
JPH0219805B2 (enExample) 1990-05-07
IE820889L (en) 1982-10-16
US4358603A (en) 1982-11-09
IE52854B1 (en) 1988-03-30
ATE9061T1 (de) 1984-09-15
AU553104B2 (en) 1986-07-03
EP0063367A1 (en) 1982-10-27
DE3260600D1 (en) 1984-09-27
AU8263582A (en) 1982-10-21
HK43987A (en) 1987-06-12
CA1168155A (en) 1984-05-29
ZA822578B (en) 1983-11-30
EP0063367B1 (en) 1984-08-22

Similar Documents

Publication Publication Date Title
DE3260600D1 (en) Acetal stabilized prostaglandin compositions
KR840000236A (ko) 포유류의 국부용 제형의 수분 손실량을 극소화시키는 방법
NZ192046A (en) Cementitious composition comprising an acid formate of ammonium, sodium or potassium as an accelerator
AU8389982A (en) Dialdehyde containing compositions
KR830002507A (ko) 옥시테트라사이클린 조성물
AU553873B2 (en) Improving the filling capacity of tobacco
DE3170818D1 (en) Composition for reducing intraocular pressure
ES2036831T3 (es) Cabeza de distribucion para un aditivo, destinada a estar montada en un recipiente, y recipiente equipado con dicha cabeza de distribucion.
ES8800598A1 (es) Un procedimiento para preparar una composicion farmaceutica que comprende azapropanona
ZA952805B (en) Stable aqueous folinate solution
SE8007569L (sv) Fosningsmedel jemte sett att dermed framstella stabila losningar lempliga for parenteral administration
GB1554048A (en) Prostacyclin derivatives
BG32858A3 (bg) Метод за получаване на кристален натриев цефамандолметанолат
IE41256B1 (en) An ether of 1-(2-hydrooxyethyl)-o-methyl-pyrazolin-5-one processes for its preparation and its use as an antithrombotic agent
MY100078A (en) Improvements relating to the expansion of tobacco.
ES484321A1 (es) Un procedimiento para la preparacion de un compuesto de 3- carbamoiloximetil-cefalosporina
AU509474B2 (en) Alcohol analogues of prostaglandins
ES395036A2 (es) Procedimiento para producir un compuesto opticamente acti- vo.
JPS5229185A (en) Semiconductor laser
GB1532550A (en) Agent for preventing cold turbidity in beer
JPS539312A (en) Preparation of light-stable mecobalamin or cobamamide parenteral injections
HUT48110A (en) Blood-analytic sampling and storing capillary tube and method for producing same
IT1169037B (it) Derivati della prostaciclina, loro preparazione e impiego
JPS532482A (en) Pyrimidine derivatives
SE8206352L (sv) Sett att framstella bensylalkoholderivat